Inve US ▾
RCRCUS

Arcus Biosciences (RCUS) Q2 FY26 earnings call: guidance and Q&A

Earnings call· Jun 2026 (Q2 FY26)· Health Care· Aug 5, 2026

Source: earnings call transcript

Executive summary

Arcus Biosciences, Inc. Q2 FY26 — Casdatifan Advances Across RCC Treatment Lines with Key Data Readouts Expected

Arcus Biosciences is rapidly advancing its oncology and immunology pipeline, with a primary focus on casdatifan, its next-generation HIF-2-alpha inhibitor, which is positioned to become a foundational therapy across all lines of clear cell RCC treatment. The company is leveraging strategic collaborations to expand its development program efficiently, while also progressing a broad immunology portfolio and preparing for key data readouts for casdatifan and quemliclustat. Strong financial positioning supports these initiatives, aiming for significant value creation.

Highlights

5

  • Casdatifan's PEAK-1 Phase III trial for second-line clear cell RCC is on track to complete enrollment by year-end 2026.

  • Multiple new clinical trial collaborations for casdatifan were initiated in the last 2 months, including with BMS, Summit Therapeutics, and AVEO, allowing Arcus to retain full rights.

  • AB102, an oral MRGPRX2 antagonist, is entering human dosing this month, with PK profile data expected in Q4 FY26.

  • Cash and investments of $775 million as of June 30, 2026, provide a runway into at least H2 2028.

  • Full-year 2026 GAAP revenue is expected to be $65 million to $75 million.

Concerns

3

  • Merck's LITESPARK-012 study failure was noted, though framed as creating an opportunity for Arcus by removing a key competitor in the frontline.

  • Collaboration revenue is expected to decrease due to the wind-down of the domvanalimab program.

  • Belzutifan has failed to show statistically significant benefit in OS in 3 out of 3 registrational trials, highlighting a potential challenge for HIF-2 inhibitors if not sufficiently potent.

Guidance & targets

CategoryTargetConfidence
PEAK-1 Phase III enrollment completion
by the end of this year
high materiality
High
PEAK-20 Phase III trial initiation
by the end of 2026
high materiality
High
AB102 human dosing initiation
this month
medium materiality
High
AB102 PK profile data readout
in the fourth quarter
medium materiality
High
Oral selective TNF receptor 1 inhibitor clinical entry
early 2027
medium materiality
High
PRISM-1 Phase III study data readout
in the first half of next year
high materiality
High
ARC-20 casdatifan data readouts
in an investor forum in October prior to ESMO
high materiality
High
Full-year 2026 GAAP revenue
$65 million to $75 million
medium materiality
High
Cash and investments balance
approximately $600 million
high materiality
High
Cash runway
into at least the second half of 2028
high materiality
High
R&D spend trajectory
meaningful decrease in overall R&D spend in 2026 and 2027 relative to 2025
medium materiality
High
Portfolio spend allocation
more than 80% of our portfolio spend to be directed toward casdatifan development
medium materiality
High
AB102 proof-of-concept study in CSU
mid-2027
medium materiality
High

Product announcements

ProductTypeDetails
AB102launch

Deals & partnerships

BMS Evaluate casdatifan in combination with pumita (bispecific anti-PD-L1/VEGF antibody) in the first-line setting.

Announced in June. BMS will evaluate two cas + pumita-based combinations in its platform study, ROSETTA RCC-208.

Summit Therapeutics Evaluate casdatifan in combination with ivo (bispecific anti-PD-1/VEGF antibody) in the first-line setting.

Announced in July. Arcus will conduct this study in a first-line cohort as part of ARC-20. Expected to begin by end of year.

AVEO Combine casdatifan with tivo in advanced belzutifan-experienced patients.

Announced in July. This study will enable a planned late-line registrational study evaluating cas-tivo in both HIF-2 inhibitor-experienced and naive patients.

Taiho Holds commercial rights to casdatifan outside of Japan and certain other Asian territories.

Arcus owns all commercial rights to casdatifan outside these territories.

Gilead Wind-down of domvanalimab program; holds an option on the TNF program.

Reduced activity under this collaboration is impacting revenue.

Risks & headwinds

Competition in frontline clear cell RCC current

Merck's LITESPARK-012 study failure

Mitigation:Casdatifan now has no competition in the frontline space as a HIF-2-alpha inhibitor, creating a clear path to consolidate the fragmented market.

Lack of overall survival benefit for belzutifan current

failed to show statistically significant benefit in OS in 3 out of 3 registrational trials

Mitigation:Arcus aims to differentiate casdatifan with early look at OS data from late-line monotherapy cohort (28 months median follow-up) and potential OS advantage in second-line cas+cabo.

Toxicity profile of Lenvatinib current

all-grade cardiac dysfunction was 7% for belz-lenva versus just 1% for cabo; Grade 3 or higher cardiac dysfunction was 5% for belz-lenva versus 0.5% for cabo

Mitigation:Arcus is combining casdatifan with cabozantinib, which has better tolerability, expecting cas+cabo to be preferred based on efficacy and safety.

Decreased collaboration revenue ongoing

Future operating results are expected to reflect lower collaboration revenue

Mitigation:Due to reduced activity under the Gilead collaboration, driven by the wind-down of the domvanalimab program. Offset by new capital-efficient collaborations.

What to watch in Q3 FY26

PEAK-1 Phase III enrollment completion

by year-end 2026
Current on track
Target completed

Why it matters

Completion of enrollment is a key milestone for the registrational study of casdatifan in second-line RCC, impacting its path to market.

PEAK-1, evaluating cas plus cabo, the gold standard of care in second-line clear cell RCC, has tremendous investigator enthusiasm, and we remain on track to complete enrollment by the end of this year.

Find out whether RCUS delivers this. Inve re-checks your case every morning.

Q&A highlights

What are the success metrics for the upcoming data, and which parts of the dataset should investors prioritize?

Terry Rosen outlined that overall success would be convincing investors that casdatifan will become the backbone standard in RCC across all lines. He highlighted the frontline opportunity as huge ($5B+ market) with no competition. For the frontline cas+ipi+nivo data, safety and primary progression rate are key. For cas+zim, ORR data with 11 months follow-up and PFS curve shape will be informative. For second-line cas+cabo, better PFS than belz-lenva and potential OS advantage over cabo are targets. For late-line monotherapy, 28 months follow-up will provide an early look at OS, demonstrating HIF-2's impact on durability.

“So at the highest level, I think we want people to walk away and believe they will walk away knowing that casdatifan is going to become the backbone standard in RCC across all lines of therapy.”

asked by Salim Syed · answered by Terry Rosen

2 min read 6 chapters

Detailed narrative

Casdatifan's Strategic Positioning in RCC

Arcus is positioning casdatifan as a foundational therapy across all lines of clear cell RCC treatment, aiming for a $5 billion to $10 billion peak sales opportunity. The company emphasizes casdatifan's superior efficacy profile over belzutifan and its potential to become the common denominator in the fragmented frontline market, especially after Merck's LITESPARK-012 study failure removed a key competitor. The development strategy is designed to provide flexibility to physicians with HIF-2-alpha inhibitor enhanced options.

Clinical Development Expansion and Collaborations

Arcus is rapidly expanding casdatifan's development program through its ARC-20 platform study and clinical collaborations, allowing it to retain full rights. Recent partnerships include BMS (cas + pumita), Summit Therapeutics (cas + ivo), and AVEO (cas + tivo). These collaborations enable investigation of mechanistic combinations in first-line and late-line settings, leveraging bispecific anti-PD-1/VEGF antibodies and existing TKIs.

Scientific Basis and Differentiation of Casdatifan

Recent research published in Nature highlights casdatifan's deep and sustained suppression of erythropoietin, correlating with higher response rates and longer progression-free survival. Management asserts that casdatifan's more robust and durable HIF-2-alpha inhibition may provide better outcomes for patients with prior TKI exposure, unlike belzutifan, which showed an inverse correlation with prior TKI therapies. This scientific differentiation underpins confidence in casdatifan's potential.

Immunology Portfolio Advancement

Arcus is building a broad immunology portfolio with several programs approaching clinical development, including AB102 (MRGPRX2 antagonist) entering human dosing this month, and an oral selective TNF receptor 1 inhibitor expected in early 2027. This portfolio targets validated and emerging mechanisms in autoimmune and allergic diseases, offering strategic optionality and addressing high unmet needs in large markets.

Quemliclustat in Pancreatic Cancer

The Phase III PRISM-1 study of quemliclustat and chemotherapy in frontline pancreatic cancer is on track for initial data readout in the first half of next year. Management sees a multi-billion-dollar commercial opportunity for quemliclustat as a well-tolerated, all-comer, first-line option that can substantially enhance the benefit of immunogenic chemotherapy.

Financial Strength and Capital Efficiency

Arcus reported $775 million in cash and investments as of June 30, 2026, with a projected runway into at least the second half of 2028. The company emphasizes capital efficiency, with new collaboration agreements structured to advance programs without significant demands on its own resources. R&D spend is expected to decrease in 2026 and 2027, with over 80% of the portfolio spend directed towards casdatifan development by 2027.

Summary of the company's earnings call; see how call summaries are prepared. Not investment advice.